12 unknown, 11 recruiting, 5 completed, 5 not yet recruiting. 41 Phase 1, 22 Phase 2.
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study Observation without surgery, Standard-of-care surgery - Non-Small Cell Lung Cancer, Immunotherapy | Phase 1 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 14 | 2026-10-01 | 2026-08-14 |
| Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS) Controlled Cold Exposure, Investigator-Selected Standard PD-1/PD-L1 Inhibitor-Based Therapy - Solid Tumors, Solid Malignancies | Phase 1 | Recruiting | West China Hospital | 24 | 2026-04-20 | 2026-05-28 |
| A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer Durvalumab or Pembrolizumab, Durvalumab or Pembrolizumab + Levnatinib, Durvalumab or Pembrolizumab + Venadaparib - Biliary Tract Neoplasms, Advanced Cancer | Phase 1 / Phase 2 | Not yet recruiting | Yonsei University | 160 | 2025-12-01 | 2025-12-08 |
| A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC ABT-301, Tislelizumab, Bevacizumab (Avastin) - Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Anbogen Therapeutics, Inc. | 66 | 2025-11-01 | 2025-11-24 |
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy | Phase 1 / Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 9 | 2025-10-29 | 2025-08-07 |
| VSV-02 Compassionate Use in Advanced Solid Tumors VSV-02 Injection - Advanced Solid Tumor, Melanoma | Phase 1 | Recruiting | The First Affiliated Hospital of Xinxiang Medical College | 6 | 2025-09-22 | 2025-12-03 |
| Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma hypofractionated radiotherapy, SOX Chemotherapy, PD-1 inhibitor - Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy | Phase 1 / Phase 2 | Recruiting | West China Hospital | 88 | 2025-09-15 | 2025-11-28 |
| A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma Tislelizumab, Afatinib, Lysogenic HSV virus. - HNSCC, Lysogenic HSV Virus | Phase 1 / Phase 2 | Active not recruiting | West China Hospital | 29 | 2025-06-10 | 2026-07-01 |
| Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC. Ketogenic diet - Cancer, Immunotherapy | Phase 1 / Phase 2 | Not yet recruiting | Rabin Medical Center | 60 | 2025-04-01 | 2025-03-26 |
| A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors Tumor Associated Lymph node T cell, Serplulimab Injection - Tumor Associated Lymph Node T Cell, Advanced Solid Tumor | Phase 1 | Recruiting | Guangzhou FineImmune Biotechnology Co., LTD. | 32 | 2025-02-13 | 2025-03-26 |
| A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus Lysogenic HSV virus., Tislelizumab, Afatinib - HNSCC, Lysogenic HSV Virus | Phase 1 | Withdrawn | West China Hospital | 2024-12-15 | 2026-10-16 | |
| Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin OBI-833/OBI-821 - Cholangiocarcinoma, Chemotherapy Effect | Phase 1 | Not yet recruiting | Chang Gung Memorial Hospital | 30 | 2024-07-31 | 2024-07-08 |
| Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Toripalimab - Cervical Cancer, Induction Chemotherapy | Phase 1 / Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 20 | 2023-11-01 | 2025-03-11 |
| Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors Tumor Associated Lymph node T cell, cyclophosphamide, IL-2 - Advanced Solid Tumor, Tumor Associated Lymph Node T Cell | Phase 1 | Recruiting | Guangzhou FineImmune Biotechnology Co., LTD. | 23 | 2023-06-06 | 2024-12-03 |
| Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC Disitamab Vedotin combined with fruquintinib and Tislelizumab - HER2-positive Gastric Cancer, Immunotherapy | Phase 1 / Phase 2 | Unknown | Fudan University | 43 | 2023-05-09 | 2023-08-09 |
| Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA SNP, Palbociclib 125mg, Bevacizumab - Cancer, Solid Tumor | Phase 1 | Recruiting | Lebanese University | 50 | 2023-02-15 | 2024-03-12 |
| Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer CAR-T cell immunotherapy - Immunotherapy | Phase 1 | Recruiting | The Affiliated Hospital of Xuzhou Medical University | 20 | 2022-12-01 | 2022-04-29 |
| A Phase I Study of GC101 TIL in Advanced Solid Tumors TIL therapy - Tumor Infiltrating Lymphocytes, Safety | Phase 1 | Completed | Shanghai Juncell Therapeutics | 43 | 2022-10-12 | 2025-12-10 |
| Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer Albumin-Bound Paclitaxel, cisplatin, Sintilimab - Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy | Phase 1 / Phase 2 | Recruiting | RenJi Hospital | 20 | 2022-01-01 | 2024-04-30 |
| Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Camrelizumab - Esophageal Neoplasm, Immunotherapy | Phase 1 / Phase 2 | Active not recruiting | Fujian Medical University Union Hospital | 25 | 2021-11-10 | 2025-11-19 |
Showing 20 of 41. Sign in to see all of them.
Neoplasms (5) · Lung Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Drug-Related Side Effects and Adverse Reactions (3) · Melanoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Renal Cell (2) · Cholangiocarcinoma (2) · Inflammation (2) · Rectal Neoplasms (2) · Biliary Tract Neoplasms (1) · Cardiovascular Diseases (1)
Neoplasms by Site (23) · Neoplasms (21) · Neoplasms by Histologic Type (10) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Carcinoma (8) · Lung Diseases (8) · Neoplasms, Glandular and Epithelial (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8) · Gastrointestinal Diseases (7) · Gastrointestinal Neoplasms (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7)
tislelizumab (4) · Immune Checkpoint Inhibitors (3) · Immunotherapy (3) · camrelizumab (3) · Afatinib (2) · Bevacizumab (2) · Biological Factors (2) · Drug Therapy (2) · Immunotherapy, Adoptive (2) · Nivolumab (2) · Radiotherapy (2) · palbociclib (2) · pembrolizumab (2) · 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide (1) · Albumin-Bound Paclitaxel (1)
West China Hospital (4) · Fudan University (2) · Guangzhou FineImmune Biotechnology Co., LTD. (2) · Lebanese University (2) · Peking University First Hospital (2) · Second Affiliated Hospital of Guangzhou Medical University (2) · The Affiliated Hospital of Xuzhou Medical University (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Ajou University School of Medicine (1) · Anbogen Therapeutics, Inc. (1) · Anhui Provincial Hospital (1) · Central Adelaide Local Health Network Incorporated (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Chang Gung Memorial Hospital (1)
China (25) · Australia (2) · France (2) · Lebanon (2) · South Korea (2) · Taiwan (2) · United States (2) · Canada (1) · Israel (1) · Netherlands (1)
Hailong Li, M.D/Ph.D (2) · Junnian Zheng, M.D/Ph.D (2) · Nehman Makdissy, Professor (2) · Qing Zhang, Ph.D (2) · Xianshu Gao, MD,PhD (2) · Xingchen Peng (2) · Zhenfeng Zhang, MD,PhD (2) · Antoine Desilets, MD, MSc (1) · Chun Chen, Dortor (1) · Chun-Nan Yeh (1) · Dong-Ho Nahm (1) · Jie Chen (1) · Liangding Hu, Prof. (1) · LiuZhong Yang, master (1)
PMID 23256743, PMID 28541315, PMID 29048935, PMID 15126782, PMID 15875784, PMID 17340590, PMID 20889925, PMID 21075954, PMID 22575238, PMID 23423337, PMID 23452187, PMID 23515080, PMID 24357284, PMID 24790793, PMID 24948466, PMID 25279468, PMID 25317870, PMID 25358763, PMID 25800393, PMID 25838375, PMID 25846669, PMID 25939063, PMID 27324428, PMID 27324746, PMID 28031562, PMID 28123387, PMID 28405515, PMID 28583311, PMID 28796558, PMID 28843072, PMID 29368638, PMID 29614760, PMID 29658848, PMID 30293387, PMID 31085757, PMID 31110702, PMID 31281894, PMID 31862474, PMID 32097050, PMID 34325726, PMID 34725214, PMID 34937871, PMID 34957526, PMID 35665739, PMID 3806806, PMID 40346524, PMID 41748259, PMID 41803866, PMID 42568612, PMID 9933432
2025 (1)